

Attorney Docket No.: 6460.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

JUL 21 2006

In re Application of: Balschmidt et al.

Confirmation No.: 9387

Application No.: 10/602,456

Group Art Unit: 1653

Filed: June 23, 2003

Examiner: Liu, Samuel W.

For: Use of Dimethyl Sulfone as Isotonicity Agent

INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than the one listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. International Search Report dated October 22, 2003

07/24/2006 TL0111 00000024 141447 10602456
02 FC:1806 180.00 DA

RECEIVED
CENTRAL FAX CENTER

020/030

JUL 21 2006


Attorney Docket No.: 6460.200-US
Application No.: 10/602,456; Filed: June 23, 2003
Inventors: Balschmidt et al.
Via Facsimile No.: 571-273-8300

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached reference.

This information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but before the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution. Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: July 21, 2006


Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Sheet 1 of 1

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6460.200-US

Serial No. 10/602,456

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Balschmidt et al.

Filing Date June 23, 2003

Group 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		International Search Report dated October 22, 2003

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.